Prostate Specific Antigen (PSA)
In updating its 2012 recommendations, the US Preventive Services Task Force changes its stance on PSA-based screening for prostate cancer in men older than 50. The new guidelines advocate for a patient-physician discussion of the benefits of testing vs the potential harms.
The decision to undergo periodic PSA screening for prostate cancer should be an individual one for men aged 55 to 69 years, according to the recommendation statement.
A review of shared decision making with men about undergoing PSA testing revealed that although full SDM discussions are increasing, variations in whether these discussions occur and how much information is shared still exist.
Researchers conducted a randomized clinical study of men to determine the impact of PSA screening on prostate cancer detection and mortality.
1. In this randomized controlled trial, men who were screened with a single PSA test had higher diagnoses of prostate cancer than those who were unscreened. 2. There was no difference in mortality between the two groups. Evidence Rating Level: 1 (Excellent) Study Rundown: In the era of prostate-specific antigen (PSA) screening, there has been 
Abiraterone acetate and prednisone reduced PSA levels in a small group of clinical trial participants with metastatic prostate cancer who did not initially respond to ADT.
Conversations about benefits and drawbacks of PSA testing improved after the USPSTF updated its recommendations on PSA testing; however, some disparities in quality of these discussions increased.
Following the USPSTF recommendation against routine PSA testing in all men, incidence rates of early stage prostate cancer in men 50 years and older declined substantially, according to a recent study.
Screening PSA levels at midlife could identify men who are at greater risk of developing prostate cancer later in life and who should be monitored more closely.
PSA levels in midlife strongly predict future lethal prostate cancer risk in U.S. cohort.
New research results favor testing for prostate specific antigen (PSA) levels for detection of prostate cancer. PSA tests can reduce the number of fatal cases of prostate cancer by detecting disease early.
A new urine assay that can detect genetic changes correlated with prostate cancer correctly identified cancer grade in 92% of men with elevated PSA levels and high-grade cancers.
Among persons 65 years or older with limited life expectancies of less than 10 years, an estimated 15.7% may have undergone nonrecommended screenings for prostate and breast cancers.
Important discussions about prostate cancer screening and treatment are not occurring between men and their health care team.
African American men with Gleason score 3+3=6 prostate cancer produce less PSA and have significantly lower PSA density than white men, according to a new study. These findings could have important implications for treatment decision-making.
Repeating PSA Test in Select Patients Can Mitigate Controversial Issues in Prostate Cancer ScreeningDecember 29, 2015
Some task forces advocate abandoning the use of the screening PSA test because it leads to unnecessary prostate biopsies. Canadian researchers show that repeating the test in select patients can reduce the number of biopsies.
The impact on PSA screening and prostate cancer incidence before and after the 2012 USPSTF screening recommendations were examined in two recent studies.
A new test is better at detecting aggressive prostate cancer than measuring PSA levels. The new test discovers aggressive cancer earlier and reduces the number of false positive tests and unnecessary biopsies.
Using watchful waiting or active surveillance to monitor men with very low- and low-risk prostate cancer is effective in many patients with localized tumors and could prevent aggressive and unnecessary treatments.
Novel test combines two markers with prostate-specific antigen (PSA) for improved prostate cancer detectionJune 08, 2015
A new test that employs urine analysis demonstrated improved prostate cancer detection over traditional models based on prostate-specific antigen (PSA) levels.
An inexpensive, quick-result test has been shown in recently published studies to be more sensitive and more exacting than the current standard test for early stage prostate cancer.
A retrospective analysis of patient data found the proportion of men with diagnoses of intermediate- and high-risk prostate cancer increased by nearly 6% between 2011 and 2013.
Prostate cancer patients with detectable prostate specific antigen (PSA) following radical prostatectomy are advised to receive more aggressive radiation therapy treatment, according to a study.
Study examines vaccine therapy in prostate cancer with rising prostate-specific antigen (PSA) levelsJanuary 23, 2015
A vaccine therapy designed to boost the body's immune response may join available early treatment options for prostate cancer.
Less than 20 percent of top-ranked health sites advise against screening for prostate cancer, a recommendation made by the USPSTF.
The presence of a particular protein in biopsied prostate tissue substantially increases the likelihood that cancer will develop in that organ. This discovery is likely to help physicians to decide how closely to monitor men who are potentially at risk for prostate cancer, which is one of the most confusing and controversial dilemmas in health care.
The proportion of men with advanced-stage prostate tumors at diagnosis has dropped dramatically since the widespread implementation of PSA screening, but the proportion of men with aggressive cancers at diagnosis has not changed substantially.
The AUA developed its new clinical guideline on castration-resistant prostate cancer by creating six index patients to represent the most common clinical scenarios encountered when managing the disease.
New guidelines from the American Urological Association advise men aged 55 to 69 years who are considering prostate cancer screening to talk with their doctors about the benefits and harms of testing.
Many older men who are found to have prostate cancer after PSA screening receive treatment despite advancing age, poor health, or low-risk disease.
Sign Up for Free e-newsletters
- Aggressive EOL Care Negatively Impacts Care Quality, Health Costs in Metastatic Lung Cancer
- Smoking Ups Risk of Myeloproliferative Neoplasms Overall and by Subtype
- Myelofibrosis: From Diagnosis to Early Intervention
- HPV Vaccination and Anti-programmed Cell Death 1 Inhibition Improve Survival in Patients With Invasive HPV-16
- FDA Approves HPV Vaccine for People Through Age 45
- Anxiety, Depression in Prostate Cancer: Managing Psychosocial Effects in Male Patients
- Tandem Autologous-Allogenic HCT Offers Long-Term Remission in Multiple Myeloma
- Tool Addresses Well-being of Informal Caregivers of Patients With Cancer
- Hematologic Cancers: 8 Tips Oncology Nurses Should Share with Caregivers
- Navigation at the End of Therapy: A Crucial Transition in Lymphoma Treatment
- Should Increased Breast Density Dictate More Breast Cancer Screenings?
- Seeking an Explanation for the Lack of Research Focused in Pediatric Oncology Therapeutics
- Prisoner or Patient? Challenges of Cancer Care in the Incarcerated Population
- Eighth AJCC TNM Staging Equalizes Distribution, Improves Prognostics of Pancreatic Cancer Stages
- Smoking Ups Risk of Myeloproliferative Neoplasms Overall and by Subtype
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|